Breast cancer is the most treatable cancer, yet it remains the leading cause of death by cancer in women—largely because national screening programs miss up to 1 in 3 cases. The problem is even worse for women with dense breasts, who make up 50% of the screening population and for whom mammography is less reliable. At The Blue Box, we've developed a urine-based breast cancer test with a high sensitivity, outperforming mammography, especially in women with dense breasts.
Looking for a breast cancer centre or clinical research facility in to co-validate The Blue Box® — a urine-based, non-invasive breast cancer detection device. The partner contributes patient recruitment (≥200 women from their screening programme).
AI
TRL 7
Oncology
Health data
Diagnostics
Bioinformatics
Clinical validation
Genitourinary system
Research collaboration
Neoplasms/cancer/oncology
Author
CEO & co-founder at The Blue Box Biomedical Solutions